Lori J Goldstein MD
Breast Cancer, Hematologic Oncology
Professor of Medicine, Temple University
Join to View Full Profile
333 Cottman Ave# FoxPhiladelphia, PA 19111
Phone+1 215-728-6900
Fax+1 215-728-3639
Dr. Goldstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1989
UPMC Medical EducationResidency, Internal Medicine, 1985 - 1986- UPMC Medical EducationResidency, Internal Medicine, 1982 - 1985
SUNY Upstate Medical UniversityClass of 1982
University of PennsylvaniaBA, Molecular Biology, Cum Laude; Brownlee Award, 1974 - 1978
Certifications & Licensure
PA State Medical License 1983 - 2026
MD State Medical License 1986 - 1992
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- Philadelphia Magazine Castle Connolly, 2004-2014
Clinical Trials
- Combination Chemotherapy in Treating Women With Breast Cancer Start of enrollment: 1998 Aug 20
- S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Start of enrollment: 2003 Oct 01
- Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer Start of enrollment: 2008 Jul 01
Publications & Presentations
PubMed
- 1 citationsCognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, Danika L Lew, William E Barlow
JAMA Oncology. 2026-02-01 - 5 citationsRace and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain
Journal of the National Cancer Institute. 2025-05-01 - What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?Emily Forester, Aakash Belsare, Dong Won Kim, Kristen Whitaker, Elias Obeid
The Journal of Surgical Research. 2024-07-01
Journal Articles
- In Support of CDK4/6 Inhibitors—A Meta-Analysis of Available Randomized DataLori Goldstein, MD, JAMA Network Open
Press Mentions
1 NCCN Guidelines for Patients® Inflammatory Breast Cancer, 2023March 23rd, 2023
Gene-Expression Profiling Raises Costs for Cancer Care Without Improving Outcomes for Low-Risk Breast Cancer Patients, According to ResearchersJanuary 22nd, 2019
Grant Support
- Eastern Cooperative Oncology GroupNational Cancer Institute2003–2011
- Development Of Breast Cancer Research Program At FcccNational Cancer Institute1994
- Breast, Prostate, Ovarian And Cervical CancerNational Cancer Institute1993
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
